Cargando…
Patient-Specific Risk Factors and Clinical Correlates of Euglycemic Diabetic Ketoacidosis in Patients on Sodium-Glucose Co-Transporter-2 Inhibitors
Background: Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT-2i) association with euglycemic diabetic ketoacidosis (EDKA) has been well reported. The underlying mechanism is mainly enhanced lipolysis and ketone bodies’ reabsorption. They also stimulate the pancreatic alpha cells and inhibit the beta...
Autores principales: | Somagutta, Manoj Reddy, Pormento, Maria Kezia Lourdes L, Hange, Namrata, Khan, Muhammad Adnan, Jain, Molly S, Hanan, Saad, Batti, Erkan, Kaur, Jaspreet, Iloeje, Obumneme Jude, Pagad, Sukrut |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090176/ http://dx.doi.org/10.1210/jendso/bvab048.967 |
Ejemplares similares
-
Euglycemic Diabetic Ketoacidosis and Sodium-Glucose Cotransporter-2 Inhibitors: A Focused Review of Pathophysiology, Risk Factors, and Triggers
por: Somagutta, Manoj R, et al.
Publicado: (2021) -
The efficacy of vitamin C, thiamine, and corticosteroid therapy in adult sepsis patients: a systematic review and meta-analysis
por: Somagutta, Manoj Kumar Reddy, et al.
Publicado: (2021) -
Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021) -
SUN-LB030 Empagliflozin Causing Euglycemic Diabetic Ketoacidosis
por: Thomas, Mathew, et al.
Publicado: (2019) -
A Case of Euglycemic Diabetic Ketoacidosis Following Canagliflozin Therapy
por: Tuna, Kubra M, et al.
Publicado: (2021)